Mahana Therapeutics

Build or buy: How should new DTx players be developing their digital treatments?
By Dave Muoio | 04:50 pm | February 12, 2021
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.